Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBIT (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBIT for 6 consecutive years, with -$71.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 5.52% year-over-year to -$71.6 million, compared with a TTM value of -$273.9 million through Sep 2025, down 25.18%, and an annual FY2024 reading of -$241.4 million, down 34.35% over the prior year.
  • EBIT was -$71.6 million for Q3 2025 at Autolus Therapeutics, down from -$61.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.0 million in Q4 2022 and bottomed at -$75.9 million in Q4 2024.
  • Average EBIT over 4 years is -$49.7 million, with a median of -$48.8 million recorded in 2023.
  • The sharpest move saw EBIT tumbled 1240.49% in 2023, then rose 1.0% in 2024.
  • Year by year, EBIT stood at -$4.0 million in 2022, then crashed by 1240.49% to -$53.3 million in 2023, then tumbled by 42.41% to -$75.9 million in 2024, then grew by 5.59% to -$71.6 million in 2025.
  • Business Quant data shows EBIT for AUTL at -$71.6 million in Q3 2025, -$61.2 million in Q2 2025, and -$65.2 million in Q1 2025.